C00021972

[PAGE 2]
SUBJECT: Sumnary of Project OFTl Clinical Tests at Eágewood

1. Funds in the enount of \$37,000 vere trarsferred to Eägewood Arsenal on 17 February l97l for the purpose of determining the clinical effects of EA f3i6?. a glycolate cless cheaicel previously developed by Edgewood. Analysis of Edgewood file data had flagged this iten as possessing unusual potential es an incapaciteat, strcnely sugsesting the possibility of

2. The Soviets were known to be actively vorkins in the slycolate area. Edgewood had partially investigated EA f3l67 and found it to be. effective in animels. In ediition, there had been several laboratory accidents in which the egent had prcduced prolonged psychotic effects in laboratory personnel.

3. Since the vere the routes of potential threet to U.S. VIP's and other key personnel, it was highly desirable that existing data on 1 in humans previously acquired by Edgevood oe extenied to incluãe ta JSimultaneously, plaas were developed to. implement counterzeasures es required.

4. Prelizinery laboretory work wes underteken to deterine the solubility end of 3l67. Aaditional work vas underteken to develop laboratory tests to identify the egent in blcod. Further work was carried out on the maskins effects of such corzon cedicinels as asprin, barbiturates. etc. The agent vas found..- | A εood solvent vas discovered. A detection test for f3167 vas eveloped,-but barbiturates vere found to completely zask its presence.

C00021972 O

12

29May 1973

MEMORANDUM FOR:

12

[PAGE 3]
weaty hu=an volunteer subjects, five prisoners (Eol=esbury
stett son, Holzesbury, Pe.) end firteen rlitary vclusteers in the
lgeki prograa vere tested. Both the
were found to be effective vith sy=ptoss lasting up to six veeks. 6. Concerning countermeasures, certain

7. In addition to the above project,in l967, established a contraet through Edgewood with for the collection of infcrnation on ená sa=ples of zew psychopharzaceuticals developed in Europe and The focus vas on urpublished áata and unusuel new developments. Agency support of this ection consisted of in 1967, end |in l969. The Ageacy took advantzge of a pre-existing contract between Ecgevood andfor the collectioa of information on foreign chezical and pharaceutical developzents. Agency redirection, beginning in l967, consisted of focusirg on psychoective drugs and on the collection of sa=ples.

8. Agency support of both the clinical testing of EA 3l67 and of the ccllecticn of information on, and sasples of foreign develop-. ments was terminated in January l973.. The transferred to Edgewood in lo72 for en enlarged foreign collection effcrt vas vithdrawn in January l973. Expenditures for the buman testing progrem were gradually reduced es subjects vere cleared froa the proeran during the necessary post-test follov-up observational end exa=inetion period.. Agency involvement in the above activities was closely held at all times.

C00021972